SCA
PTCT icon

Spearhead Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

Spearhead Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,448
Closed -$298K – 145
2022
Q2 		$298K Sell
7,448
-105
-1% -$3.68K 0.04% 128
2022
Q1 		$282K Sell
7,553
-513
-6% -$19.8K 0.03% 145
2021
Q4 		$321K Buy
8,066
+140
+2% +$5.36K 0.04% 141
2021
Q3 		$295K Sell
7,926
-36
-0.5% -$1.48K 0.04% 155
2021
Q2 		$337K Buy
7,962
+1,463
+23% +$62.7K 0.05% 168
2021
Q1 		$308K Buy
+6,499
New +$386K 0.05% 164

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Spearhead Capital Advisors's PTCT Position: Q3 2022 in Review

Spearhead Capital Advisors sold out of PTC Therapeutics (PTCT) in Q3 2022, closing a stake of 7,448 shares — an estimated $298K sold.

Spearhead Capital Advisors first reported a position in PTCT in Q1 2021 and held it in 6 quarters. The position peaked at $337K in Q2 2021. 213 funds tracked by Wall St. Rank hold PTCT as of Q3 2022.

  • Spearhead Capital Advisors reported no remaining PTC Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 7,448 PTC Therapeutics shares in Q3 2022, an estimated $298K.
  • Spearhead Capital Advisors first reported a position in PTC Therapeutics in Q1 2021 and held it in 6 quarters.
  • Spearhead Capital Advisors's PTC Therapeutics position peaked at $337K in Q2 2021.
  • 213 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2022.

Based on Spearhead Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.